Bit.bio company that combines synthetic and stem cell biology, has raised £103 in Serie B round. Founder and CEO Dr Mark Kotter said: “I’m thrilled that bit.bio is supported by world class investors and strategic partners. The capital will enable us to accelerate our clinical and commercial scale-up and to deliver cell therapies for every patient, everywhere.”
Bit.bio was previously on Accelerate Cambridge programme run by Cambridge Judge’s Entrepreneurship Centre.
Read the full article [businessweekly.co.uk]